Clinical Trial Policy Study for the Objective Comparison of Cannabis Vs Opioids (CVO) Pain Management and Therapy Types for Circulatory and Chronic Pain Issues

Our purpose for the study is to find safer, less intrusive, better preforming non-addictive products, as an alternative therapy for pain relief and to help alleviate the opioid epidemic ongoing in America today.

开始日期2026-06-03

申办/合作机构

American Association of Sensory Electrodiagnostic Medicine

NCT07422311

/ Not yet recruiting临床2/3期

A Phase 2/3, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Dronabinol Oral Solution for Agitation in Patients With Alzheimer's Disease

This study tests a medication called dronabinol in people with Alzheimer's disease. First, participants go through up to 4 weeks of screening. Then, over 2 weeks, the dose of the study drug is slowly increased. For the next 10 weeks, participants stay on either dronabinol or a placebo.
After finishing this part of the study, participants can join a 6-month extension where everyone receives dronabinol. Those already on the drug stay on their same dose, while those who were on placebo gradually increase their dose over 2 weeks.
All participants take dronabinol for the rest of the extension, then complete a final safety check 4 weeks after stopping the medication. Usual medical treatments are continued throughout the study.

开始日期2026-05-01

申办/合作机构

Benuvia Therapeutics, Inc.

[+1]

100 项与屈大麻酚相关的临床结果

登录后查看更多信息

100 项与屈大麻酚相关的转化医学

登录后查看更多信息

100 项与屈大麻酚相关的专利（医药）

登录后查看更多信息

12,338

项与屈大麻酚相关的文献（医药）

2026-07-01·TALANTA

Portable voltammetric method for the simultaneous determination of Δ9-Tetrahydrocannabinol and cannabidiol in alkaline medium using unmodified screen-printed carbon electrodes

Article

作者: Pedão, Evandro R ; Lucca, Bruno G ; Lima, Camila D ; Brandão, Mariane O ; Gebara, Sâmya S ; Guerbas, Fernanda M R ; Moraes, Natália C ; Arantes, Luciano C ; Dos Santos, Wallans T P

Simultaneous detection of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is crucial for the analysis of seized materials and cannabis-based preparations. To address this need, a simple, rapid, and selective electrochemical method was developed for the preliminary detection and quantification of both cannabinoids. The proposed method employs unmodified carbon screen-printed electrodes (carbon-SPEs) in a strongly alkaline medium (0.5 mol L^-1 NaOH solution). The electrochemical behaviors of THC and CBD were investigated over a wide range of pH values, enabling a simultaneous detection with distinct peak potentials observed on carbon-SPE (vs Ag). THC exhibited a single irreversible oxidation process (O_1T) on the carbon-SPE surface, whereas CBD showed, for the first time, five well-defined electrochemical processes, with two reduction processes (R_1C and R_2C) and three oxidation processes (O_1C, O_2C and O_3C). Square wave voltammetric technique was optimized for the simultaneous determination of THC and CBD using their oxidation processes at O_1T and O_3C on carbon-SPE, with limits of detection of 0.09 μmol L^-1 and 2.72 μmol L^-1, respectively. Moreover, consistent electrochemical responses were obtained using either the same (N = 5) or different SPEs (N = 3), with RSDs lower than 5.6% and 2.0 % for peak currents and peak potentials, respectively. Method applicability was confirmed by analyzing thirty-five (35) real seized samples and seven cannabis-based products, showing good agreement with GC-MS results. Addition-recovery studies using real seized samples yielded values close to 100 % for both analytes: 102 ± 2 % for O_1T (THC) and 103.3 ± 0.8 % for O_3C (CBD). These findings highlight the method's potential as a reliable, low-cost, and field-deployable tool for forensic screening and quality control in cannabis-derived products.

2026-06-01·Toxicology reports

The toxicology of orally administered Δ9-tetrahydrocannabinol in sheep

Article

作者: May, Christopher D ; Krebs, Gaye L ; Blake, Bronwyn L ; Stevens, Sarah A ; Noble, Glenys K ; Petzel, Christopher E ; Tai, Zi Xuan ; Edwards, Scott H ; Scrivener, Colin J ; Dods, Kenneth C ; Warne, Leon N

Introduction:

As part of a larger study to assess the potential value of industrial hemp biomass (the low Δ⁹-tetrahydrocannabinol (Δ⁹-THC) variety of Cannabis sativa L.) as a feed for ruminants, a pharmacokinetics study of Δ⁹-THC, one of the main cannabinoids of interest, was undertaken. In undertaking this study, the toxicology of orally administered Δ⁹-THC was incidentally investigated and was discussed in the current paper.

Methods:

Eight Merino ewes were administered with two per os (PO) doses of 88.5 mg Δ⁹-THC/kg bodyweight (BW) 12 h apart. Blood samples were taken periodically to determine the pharmacokinetics of Δ⁹-THC but also to check blood troponin I concentrations post dose administration as in the pharmacokinetics study there were adverse effects to the heart following intravenous administration of Δ⁹-THC.

Results:

Following the PO dose of Δ⁹-THC, the pharmacokinetics were able to be determined (and were published separately); however, significant adverse clinical signs were observed in the sheep. Clinical signs included ataxia (stumbling, swaying), abnormal posture (head held low, head resting on the wall of the pen, back legs crossed over), somnolence, wool pulling, increased salivation, a prolonged reduction in feed intake and consequent decrease in BW. Plasma troponin I concentrations were elevated in three of the eight sheep following the PO dose of Δ⁹-THC.

Conclusions:

The adverse clinical signs noted have implications for iHemp biomass as a potential feed for ruminants due to both animal health and production effects. Further research is required to investigate appropriate feeding strategies for iHemp biomass to be utilised as a feed for ruminants.

2026-06-01·FISH & SHELLFISH IMMUNOLOGY

Sampling conditions affect immune cell viability and function in the Mediterranean mussel (Mytilus galloprovincialis)

Article

作者: De Iorio, Teresina ; Profico, Chiara ; Di Francesco, Gabriella ; Martinoli, Marco ; Martini, Arianna ; Di Giacinto, Federica ; Napolitano, Riccardo ; Capoccioni, Fabrizio ; Tonachella, Nicolò ; Pulcini, Domitilla

Farmed animal welfare is becoming a socially relevant issue. Several strategies have been developed to assess the welfare of farmed animals in vitro, including the evaluation of immune functions. The appropriate isolation of immune cells plays a key role in studying in vitro cell functions. This study aims to evaluate the best sampling conditions to promote the viability and immune functions of Mediterranean mussel (Mytilus galloprovincialis) hemocytes. Mussels were divided into 4 groups, based on the solution used for sampling: Modified Leibovitz's 15 medium (mL15), Lithium Heparin+mL15 (LiH+mL15), Modified Alsever's Solution (MAS), and Filtered SeaWater (FSW). Hemolymph was collected, and the total hemocyte count (THC), membrane-glycoprotein retention, viability, and phagocytosis were examined. The MAS group showed significantly higher THC compared to the other groups, while the highest glycoprotein retention was observed in LiH+mL15. In vitro incubation time did not influence hemocyte viability, but hemocytes sampled with LiH+mL15 showed higher viability compared to the MAS and FSW groups. The LiH+mL15 group also displayed greater phagocytic capacity. The results indicate that MAS is recommended for the THC, while, for functional studies, it is suggested to use LiH+mL15, as it best preserves hemocyte viability, membrane glycoproteins, and phagocytic activity and capacity.

625

项与屈大麻酚相关的新闻（医药）

2026-03-11

·Science Daily

Cannabis study finds THC can create false memories

THC doesn’t just blur memories—it can create new ones that never happened. In a controlled experiment, cannabis users were much more likely to recall words that were never shown and struggled with tasks like remembering to do something later. Researchers found that THC disrupted many different memory systems at once. Surprisingly, moderate doses caused memory problems similar to higher doses.Smoking cannabis may do more than make memories fuzzy. It may actually alter how memories form and are recalled. A new study from Washington State University found that people who consumed THC were more likely to recall words that were never shown to them and had more trouble completing everyday memory tasks, such as remembering to do something later. Published in the Journal of Psychopharmacology, the research provides one of the most detailed examinations to date of how cannabis influences memory. The results indicate that cannabis affects not only simple recall, like remembering a list of words, but also several forms of memory that people rely on throughout the day. These include remembering appointments, keeping track of conversations, and identifying where information originally came from. Researchers were also surprised to see no meaningful differences between participants who consumed 20 milligrams of THC and those who consumed 40 milligrams. This finding suggests that even moderate amounts of THC may significantly interfere with memory. Study Examines Multiple Memory Systems "Most previous studies have only looked at one or two types of memory, like recalling lists of words," said Carrie Cuttler, senior author of the study and an associate professor of psychology at WSU. "This is the first study to comprehensively examine many different memory systems at once, and what we found is that acute cannabis intoxication appears to broadly disrupt most of them." To investigate these effects, Cuttler and co-author Ryan McLaughlin, an associate professor in the Department of Integrative Physiology and Neuroscience at WSU, recruited 120 regular cannabis users. Participants were randomly assigned to vaporize placebo cannabis, 20 milligrams of THC, or 40 milligrams of THC in a double-blind experiment. After consuming the assigned substance, participants completed roughly an hour of memory tests. The assessments measured several types of memory, including verbal, visuospatial, prospective, source, false, episodic content, and temporal order memory. People who consumed cannabis performed significantly worse than those who received the placebo on most of the tests. In total, cannabis affected the majority of the memory measures, with significant differences appearing in 15 of the 21 tests. Cannabis Linked to False Memories and Source Confusion The most pronounced effects were seen in false memory and source memory, which help people accurately recall information and determine where that information came from. In one test, participants listened to lists of related words that were connected by a theme, but the central keyword tying them together was never spoken. Later, individuals who had consumed cannabis were more likely to say they remembered hearing words that had not been presented. "I found it was really common for people to come up with words that were never on the list," Cuttler said. "Sometimes they were related to the theme of the list, and sometimes they were completely unrelated." Participants who used cannabis also had more difficulty identifying where previously learned information originated. Problems with source memory can make it harder to determine whether information came from a trusted source, a conversation, or something encountered online. These kinds of memory distortions could have serious implications in situations where accurate recall is essential. For example, errors in memory or suggestive questioning during eyewitness interviews can influence how events are remembered. Impacts on Everyday Memory Tasks The researchers also observed impairments in prospective memory, which is the ability to remember to perform tasks in the future. This type of memory is involved in everyday responsibilities such as taking medication, attending meetings, or stopping at the store on the way home. "These are things we rely on constantly in our day-to-day lives," Cuttler said. "If you have something you need to remember to do later, you probably don't want to be high at the time you need to remember to do it." One form of memory called episodic content memory, which involves recalling personal experiences, did not show a significant effect in this study. Cuttler noted that additional research is needed before drawing firm conclusions about that type of memory. Cannabis Use Is Growing but Research Gaps Remain The study comes at a time when cannabis use is becoming increasingly common in states such as Washington. Even though legalization has expanded across North America, many short term cognitive effects of cannabis remain unclear. One reason for the limited research is that cannabis is still classified as a Schedule I substance under federal law, which has historically restricted scientific study. "We're living in a state where cannabis use is very common, but there's still a lot we don't know about its acute effects," Cuttler said. "The goal is to help people make informed decisions about the risks and benefits."

2026-03-10

·GlobeNewswire-Health Care

SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails

TEL AVIV, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, has entered into a definitive share purchase agreement (the "SPA"), between NeuroThera, CliniQuantum Ltd. (“CliniQ”) and the Selling Shareholders (as defined below) to acquire approximately 54.01% of the issued and outstanding ordinary shares of CliniQ (the "CliniQ Shares") on a fully diluted basis immediately prior to the closing of the transaction (the “Transaction”). CliniQ is a quantum technology company holding patents from Ramot at the Tel Aviv University, in the field of quantum simulation and quantum Monte Claro. CliniQ develops a next-generation platform to transform clinical trials with the power of quantum computing. Its aim is to unlock insights hidden in massive, complex datasets to design smarter, faster, and more adaptive studies. Transaction Overview Under the SPA, NeuroThera will acquire 56,375 CliniQ Shares (the "Purchased Shares"), representing approximately 54.01% of the issued and outstanding ordinary shares of CliniQ from certain shareholders of CliniQ (collectively, the "Selling Shareholders"). In consideration for the Purchased Shares, NeuroThera will issue an aggregate of 56,600,000 common shares from the capital of NeuroThera (the "Consideration Shares") to the Selling Shareholders, representing an aggregate value of approximately $9,459,954.20 based on the volume weighted average trading price of the NeuroThera's common shares on the TSX Venture Exchange (the "TSXV") for the 20 trading days immediately preceding the date of the determination. In addition to the Consideration Shares, the Selling Shareholders may be entitled to receive earn-out payments of up to $2,500,000 in the aggregate (the "Earn-Out Payments"), payable in cash and/or common shares of NeuroThera at the sole discretion of NeuroThera, contingent upon the achievement of the certain milestones, including $500,000 for each of the first three patent applications filed by CliniQ with the United States Patent and Trademark Office or the European Patent Office, up to a maximum of $1,500,000 in the aggregate filed during the Earn-Out Period (as defined below); and an amount equal to 7.0% of any fundraising proceeds raised by NeuroThera, up to a maximum of $1,000,000 in the aggregate. The Earn-Out Payments, if any, are payable during the three-year period following the closing of the Transaction (the “Earn-Out Period”). Closing of the Transaction is expected to occur within 30 days following the submission of the application for the Israeli tax ruling to the Israeli Tax Authority, subject to satisfaction or waiver of all closing conditions. The closing of the Transaction is anticipated to be on or about March 31, 2026, unless otherwise agreed by the parties in writing. About SciSparc Ltd. (Nasdaq: SPRC): The Company, through its majority-owned subsidiary NeuroThera Labs Inc., engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera Labs Inc., are currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. The Company, through NeuroThera Labs Inc., also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace. About NeuroThera Labs Inc. NeuroThera Labs Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations. Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the closing of the Transaction, which is subject to satisfaction or waiver of all closing conditions, and timing thereof and that the Selling Shareholders may be entitled to the Earn-Out Payments. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F, as amended, filed with the SEC on April 24, 2025, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact:IR@scisparc.comTel: +972-3-6167055

2026-03-02

·GlobeNewswire-Health Care

SciSparc Announces 1-for-9 Reverse Share Split

Following the reverse share split, the Company will have approximately 565,000 outstanding shares, out of which approximately 561,533 will be publicly held Tel Aviv, Israel, March 02, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (“SciSparc” or the “Company”) (Nasdaq: SPRC), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today that it intends to effect a one-for-nine (1-for-9) reverse share split (the “Reverse Share Split”) of the Company’s issued and outstanding ordinary shares, no par value per share (the “Ordinary Shares”), effective at the market open on March 4, 2026. The Ordinary Shares will continue to trade on the Nasdaq Capital Market under the existing trading symbol “SPRC” and will begin trading on a split-adjusted basis at the market open on March 4, 2026. The new CUSIP number for the Ordinary Shares following the Reverse Share Split will be M82618139. The Reverse Share Split was approved by the Company’s shareholders at the Company’s Annual General Meeting of Shareholders held on June 26, 2025, to be effected at the board of directors’ discretion within the approved parameters. The Reverse Share Split will not result in an adjustment to the authorized share capital of the Company under the Company’s amended and restated articles of association, as currently in effect (the “Articles”), which, as of the date hereof, consists of 2,000,000,000 Ordinary Shares. The Reverse Share Split will affect all shareholders uniformly and will not alter any shareholder’s percentage of ownership interest in the Company’s Ordinary Shares, except for minor changes due to the treatment of fractional shares as described below. The number of issued and outstanding Ordinary Shares will be reduced from 5,089,501 Ordinary Shares to approximately 565,500 Ordinary Shares following the Reverse Share Split (subject to any further adjustments due to the treatment of fractional shares). In accordance with the Articles, no fractional Ordinary Shares will be issued as a result of the Reverse Share Split and all fractional Ordinary Shares shall be rounded to the nearest whole Ordinary Share, at the DTC participant level. In addition, a proportionate adjustment will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding options and warrants entitling the holders to purchase Ordinary Shares. No fractional Ordinary Shares will be issued upon exercise of warrants or options. As to any fraction of an Ordinary Share which a holder would otherwise be entitled to purchase upon exercise, the Company will round up to the nearest whole Ordinary Share, according to the terms of the warrant or option. Shareholders holding their shares in book-entry form, through a brokerage account, or in “street name” are not required to take any action, as the exchange will be processed automatically by their respective brokers or custodians. For questions or additional information regarding the exchange process, shareholders are encouraged to contact the Company’s transfer agent, VStock Transfer, LLC with a mailing address of 18 Lafayette Place, Woodmere, New York 11598. About SciSparc Ltd. (Nasdaq: SPRC): The Company, through its majority-owned subsidiary NeuroThera Labs Inc., engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera Labs Inc., are currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. The Company, through NeuroThera Labs Inc., also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace. Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward-looking statements when discussing the anticipated effective date of the Reverse Share Split and the date that trading of the Ordinary Shares will begin on a split-adjusted basis. Since such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact:IR@scisparc.comTel: +972-3-6167055

100 项与屈大麻酚相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00306	屈大麻酚	A04AD10	DB00470

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
厌食症	美国	Alkem Laboratories Ltd.	1985-05-31
恶心	美国	Alkem Laboratories Ltd.	1985-05-31
呕吐	美国	Alkem Laboratories Ltd.	1985-05-31

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
化疗引起的恶心和呕吐	申请上市	加拿大	Tetra Bio-Pharma, Inc.	2023-05-01
痴呆引起的激越	临床3期	澳大利亚	Benuvia Therapeutics, Inc.	2026-05-01
阿尔茨海默症	临床3期	澳大利亚	Benuvia Therapeutics, Inc.	2026-05-01
阻塞性睡眠呼吸暂停综合征	临床3期	美国	RespireRx Pharmaceuticals, Inc.	2023-02-01
腰痛	临床3期	德国	Vertanical GmbH	2021-07-07
食欲减退	临床3期	欧洲	Solvay SA	2007-02-15
Tourette 综合征	临床2期	美国	SciSparc Ltd.	2017-02-01
抑郁症	临床2期	美国	Unimed Pharmaceutical, Inc.	1996-07-29
帕金森病	临床前	加拿大	Pike Therapeutics, Inc.	2024-11-01
认知障碍	临床前	以色列	Therapix Biosciences Ltd /Non-Pain Assets/	2018-05-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASH2025	临床2期	慢性疼痛 \| 镰状细胞血症	30	Dronabinol	廠壓積襯糧選鑰衊糧糧(網獵網夢窪築膚願蓋齋) = 構夢齋築繭獵廠齋鏇窪蓋壓繭廠鏇獵膚蓋鹽選 (餘獵艱淵餘憲顧鬱衊醖 ) 更多	积极	2025-12-06
				Placebo	廠壓積襯糧選鑰衊糧糧(網獵網夢窪築膚願蓋齋) = 膚淵廠蓋遞蓋願構遞鏇蓋壓繭廠鏇獵膚蓋鹽選 (餘獵艱淵餘憲顧鬱衊醖 ) 更多
NCT03978156 (Pubmed \| Pilot Feasibility Stud)	临床2期	镰状细胞血症	6	Dronabinol	繭網壓遞衊遞艱襯夢積(廠壓範遞艱鏇選壓獵廠) = 餘範網膚廠範繭衊簾廠鹹積糧網衊遞願鹹積構 (範齋蓋網憲鏇鏇壓窪餘 ) 更多	积极	2025-11-12
NCT02792257 (THC-AD, Pubmed \| Am J Geriatr Psychiatry)	临床2期	痴呆引起的激越	75	Dronabinol	憲網積願選淵築遞醖鹹(鏇鹹鬱夢顧衊築範憲壓): Difference = -1.26, P-Value = 0.094 更多	积极	2025-11-01
				Placebo
NCT05610813 (Pubmed \| Pain Ther)	临床3期	腰痛	384	VER-01	夢簾鬱簾遞網餘選糧醖(鑰鏇顧糧淵築壓簾鑰鏇) = 鬱製夢衊醖構襯膚襯鑰簾選選願構齋憲醖淵鹽 (觸鹹艱襯壓窪夢壓憲顧 ) 更多	积极	2025-09-30
				Opioids	願鬱夢鹹願鏇窪範鹹觸(構願構窪餘繭獵顧簾齋) = 觸衊齋襯蓋襯壓廠餘糧醖夢醖糧醖淵獵壓膚範 (淵範遞蓋構顧衊鹽夢襯 ) 更多
NCT05477875 (CTgov)	临床2期	近视 \| 远视 \| 术后疼痛	35	Cannabidiol (Cannabidiol)	窪艱鑰壓繭蓋製襯網醖(醖淵糧窪糧顧築願範憲) = 鑰繭鏇艱範願蓋鹽夢觸繭觸顧製艱艱鏇鹽廠窪 (衊鑰獵醖窪構鏇壓餘糧, 0.95) 更多	-	2025-08-07
				Tylenol T3 (Tylenol T3)	窪艱鑰壓繭蓋製襯網醖(醖淵糧窪糧顧築願範憲) = 壓衊襯製醖淵膚構艱膚繭觸顧製艱艱鏇鹽廠窪 (衊鑰獵醖窪構鏇壓餘糧, 0.89) 更多
NCT05820685 (DOPE, CTgov)	临床4期	疼痛	484	Standard of Care (Standard of Care)	艱願窪構鏇膚願憲願夢(製網選淵顧齋製糧鬱製) = 艱鹽襯艱餘壓鏇廠餘構憲網襯獵齋鏇齋鬱鑰膚 (壓鹹選夢遞膚鏇夢鹽製, 夢鏇網餘鹽選網窪獵構 ~ 鏇築築夢襯糧夢鹹淵窪) 更多	-	2025-06-11
				Standard of Care+Dronabinol (Standard of Care + Dronabinol)	艱願窪構鏇膚願憲願夢(製網選淵顧齋製糧鬱製) = 顧鏇夢繭壓獵獵憲網醖憲網襯獵齋鏇齋鬱鑰膚 (壓鹹選夢遞膚鏇夢鹽製, 選獵選壓壓顧繭憲簾遞 ~ 遞觸廠築積鏇顧網選淵) 更多
NCT02792257 (THC-AD, CTgov)	临床2期	阿尔茨海默症 \| 躁动	84	Dronabinol (Dronabinol)	襯顧繭製餘膚觸膚願網(簾廠選鬱遞廠憲憲鏇夢) = 衊襯鏇齋築窪顧網築範範蓋蓋顧窪顧範衊鏇積 (築艱齋襯艱醖夢窪夢積, 4.12) 更多	-	2025-05-09
				Placebo (Placebo)	襯顧繭製餘膚觸膚願網(簾廠選鬱遞廠憲憲鏇夢) = 齋鑰憲淵壓網願觸製鑰範蓋蓋顧窪顧範衊鏇積 (築艱齋襯艱醖夢窪夢積, 4.18) 更多
NCT03705559 (CTgov)	临床1期	大麻滥用	10	Placebo (Placebo/Placebo)	鹹構膚範遞鹹鏇構製醖(觸製艱蓋鹹鑰襯鏇艱觸) = 膚顧蓋鬱觸繭鹽鬱醖壓鹽選襯簾廠築獵選淵淵 (醖獵衊壓鹹鬱壓膚網鹹, 1.83) 更多	-	2025-04-10
				Placebo+THC (THC 10mg/Placebo Opioid)	鹹構膚範遞鹹鏇構製醖(觸製艱蓋鹹鑰襯鏇艱觸) = 鹹觸淵構鹹願繭鑰襯願鹽選襯簾廠築獵選淵淵 (醖獵衊壓鹹鬱壓膚網鹹, 10.03) 更多
NCT02817698 (CTgov)	早期临床1期	吸烟 \| 大麻滥用 \| 未指明的药物依赖	25	cannabis	餘衊顧蓋鹹鑰窪範築窪(艱網願蓋鹹窪齋鑰繭蓋) = 觸築鏇選鑰選製觸繭簾艱鑰醖遞範膚衊鬱餘範 (餘選獵憲鬱鬱衊窪願齋, 廠醖糧選憲衊醖鬱顧網 ~ 齋遞獵鑰構醖積構蓋鹽) 更多	-	2024-12-12
NTIASD1 (Company_Website) 人工标引	临床1/2期	自闭症谱系障碍	14	NTI164	衊鑰蓋醖襯鑰遞觸遞願(製壓選醖顧鹽構網築齋) = 窪範鏇艱膚鬱積齋衊簾遞繭窪繭構壓艱壓願遞 (廠壓窪餘餘獵餘糧膚糧 )	积极	2024-12-01